Quarterly report pursuant to Section 13 or 15(d)

License Agreement Revenue - Additional Information (Detail)

v3.21.2
License Agreement Revenue - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Feb. 28, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Income tax expense $ (4,138,000) $ (3,144,000) $ (3,038,000) $ (3,144,000)  
Exclusive License And Collaboration Agreement          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Non refundable upfront payment received     10,000,000.0    
Transaction price     12,100,000    
Fixed upfront cash payment     10,000,000.0    
Amount related to withholding tax obligations     1,100,000    
Revenue recognized     1,100,000    
Income tax expense     1,100,000    
Exclusive License And Collaboration Agreement | Maximum          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Potential development and commercial milestones yet to receive         $ 110,000,000.0
Asset Purchase Agreement | Cypralis Limited          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Revenue recognized 0   0    
License Agreement | Waterstone Pharmaceutical HK Limited          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Revenue recognized $ 0   $ 0